Why the study?
Does candesartan cilexetil or hydralazine prevent the progression of preglomerular sudanophilic lesions in L-NAME hypertensive rats?
Population
Rats with systemic hypertension and progressive preglomerular sudanophilic lesions induced by chronic…
Comparison
Candesartan cilexetil or hydralazine… vs L-NAME treatment alone without antihypertensive…
Design
Preclinical
Follow-up
2 weeks of intervention
Loading...
Offers no immediate clinical guidance in hypertension; extends preclinical ARB data on vascular lesions but leaves human translation open.
Does candesartan cilexetil or hydralazine prevent the progression of preglomerular sudanophilic lesions in L-NAME hypertensive rats?
Angiotensin II type 1 receptor blockade with candesartan prevents the progression of preglomerular sudanophilic lesions in L-NAME-induced hypertension in rats, partly through pressure-lowering effects.
A 1999 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: